Marker Therapeutics (NASDAQ:MRKR – Get Free Report) issued its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02, Zacks reports.
Marker Therapeutics Price Performance
Shares of NASDAQ:MRKR traded down $0.04 during midday trading on Monday, reaching $0.83. 135,857 shares of the company’s stock were exchanged, compared to its average volume of 151,414. The firm’s 50 day simple moving average is $1.06 and its two-hundred day simple moving average is $1.32. The stock has a market cap of $13.81 million, a price-to-earnings ratio of -2.02 and a beta of 1.65. Marker Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.46.
Analyst Ratings Changes
MRKR has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Weiss Ratings lowered shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Marker Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.
About Marker Therapeutics
Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.
Read More
- Five stocks we like better than Marker Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
